Enterin Inc. Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

Enterin Inc. is a privately held biotechnology company based in Philadelphia, Pennsylvania, focused on therapies that repair the gut-brain axis in neurodegenerative diseases. Its lead compound, ENT-01 (kenterin), aims to displace membrane-bound alpha-synuclein aggregates from enteric nerve cells and improve signaling between the gut and brain, with preclinical models in Parkinson's disease showing enhanced gut motility. The firm is advancing ENT-01 through clinical development to address constipation associated with Parkinson's disease and potentially related conditions. Enterin positions itself within the biotechnology research sector by pursuing therapies that restore gut-brain axis function to improve patient outcomes in Parkinson's and other neurodegenerative diseases. In 2022, the company announced the initiation of a Phase 2 trial evaluating ENT-01 for Parkinson's disease–associated dementia, signaling an expansion of its clinical program.

Get verified Enterin Inc. emails free

Company overview Employee directory